{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:20:34Z","timestamp":1787642434566,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ministry of Health, Labour, and Welfare of Japan","award":["H29-nanchitou(nan)-ippan-018, 20FC1044, and 20FC1033"],"award-info":[{"award-number":["H29-nanchitou(nan)-ippan-018, 20FC1044, and 20FC1033"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,18]]},"DOI":"10.1093\/mr\/roab104","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T01:48:18Z","timestamp":1641347298000},"page":"475-483","source":"Crossref","is-referenced-by-count":20,"title":["RETRACTED: Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicin , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Takada","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicin , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"2022042010130692900_R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022042010130692900_R2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","article-title":"2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2022042010130692900_R3","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology"},{"key":"2022042010130692900_R4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2022042010130692900_R5","first-page":"123","article-title":"Breaking down the complement system: a review and update on novel therapies","volume":"26","author":"Reddy","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022042010130692900_R6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2022042010130692900_R7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2022042010130692900_R8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3904\/kjim.2018.366","article-title":"Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis","volume":"34","author":"Harigai","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2022042010130692900_R9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"2022042010130692900_R10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"2022042010130692900_R11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.ki.5002103","article-title":"Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice","volume":"71","author":"Huugen","year":"2007","journal-title":"Kidney Int"},{"key":"2022042010130692900_R12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"2022042010130692900_R13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022042010130692900_R14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022042010130692900_R15","doi-asserted-by":"crossref","first-page":"E9618","DOI":"10.1073\/pnas.1708247114","article-title":"Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis","volume":"114","author":"Schreiber","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022042010130692900_R16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2022042010130692900_R17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"2022042010130692900_R18","article-title":"Japanese Package Insert for Avaopan","author":"Japan Ministry of Health, Labour, and Welfare"},{"key":"2022042010130692900_R19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2022042010130692900_R20","doi-asserted-by":"crossref","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022042010130692900_R21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0815-y","article-title":"Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study","volume":"17","author":"Sada","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022042010130692900_R22","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab104\/42110486\/roab104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/3\/475\/43400595\/roab104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/3\/475\/43400595\/roab104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:51:50Z","timestamp":1787640710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/3\/475\/6497529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,1,4]]},"published-print":{"date-parts":[[2022,4,18]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab104","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,1,4]]}}}